Work under heat.
Evidence before field use.

National-security research brief | Preclinical drug development

The readiness problem (2025 data; May 2026 report)

MSMR 2025: 518 heat-stroke and 2,233 heat-exhaustion cases in active-component service members; heat-stroke incidence up 6.9%, heat-exhaustion down 9.1%.

The lead question

Does bemitil preserve work capacity under heat? Bemitil is a Soviet-era actoprotector and the company's lead molecule. Human efficacy is unproven.

The human starting point

1997 human heat/exertion reports (PMID 9162292, companion 9235216). Thermal tolerance and work capacity effects described; phenibut or its combination performed best; a bemitil-specific effect size is not available in the abstracts.

The financed decision

Raising $1-2M pre-seed. The illustrative $1.5M plan covers 18 months. Months 0-3: leadership, authenticated material, locked thresholds. Months 3-9: molecular profiling, functional heat testing, independent confirmation. Stop candidate advancement at month nine for failed replication or unacceptable safety.

Domestic development is a secondary goal

US API supply and domestic development partners are company goals. No scientific lead is hired. No lab is contracted. No US API production or government partnership is secured.

Cost and readiness limits

[HEAT ATTRITION COST: verified figure and source]. No monetary savings estimate or field-ready capability is claimed. The program is a research proposition, not a procurement-ready product.

Research sponsors: science@antaeusbiosciences.com
Evidence, regulatory route, and allocation: antaeus.bio/natsec